2020
Clinical outcomes of older patients with AML receiving hypomethylating agents: a large population-based study in the United States
Zeidan AM, Wang R, Wang X, Shallis RM, Podoltsev NA, Bewersdorf JP, Huntington SF, Neparidze N, Giri S, Gore SD, Davidoff AJ, Ma X. Clinical outcomes of older patients with AML receiving hypomethylating agents: a large population-based study in the United States. Blood Advances 2020, 4: 2192-2201. PMID: 32433746, PMCID: PMC7252544, DOI: 10.1182/bloodadvances.2020001779.Peer-Reviewed Original ResearchConceptsAcute myeloid leukemiaDecitabine-treated patientsTransfusion independenceRed blood cell transfusion independenceLarge population-based studyOlder AML patientsRBC transfusion independenceEnd Results-MedicarePopulation-based studyStandard of careAgent azacitidineMedian survivalOlder patientsIntensive therapyAML patientsClinical outcomesClinical benefitMyeloid leukemiaMortality riskPatientsAzacitidineDecitabineOlder adultsOne-thirdMeaningful differences
2019
The Impact of the 2011 European Leukemianet (ELN) Guidelines for Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms on Therapeutic Phlebotomy and Hydroxyurea Use in Patients with Polycythemia Vera and Essential Thrombocythemia
Podoltsev N, Wang R, Shallis R, Huntington S, Zeidan A, Gore S, Davidoff A, Ma X. The Impact of the 2011 European Leukemianet (ELN) Guidelines for Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms on Therapeutic Phlebotomy and Hydroxyurea Use in Patients with Polycythemia Vera and Essential Thrombocythemia. Blood 2019, 134: 2125. DOI: 10.1182/blood-2019-127563.Peer-Reviewed Original ResearchTherapeutic phlebotomyPopulation-based cohortPV patientsELN guidelinesET patientsPolycythemia veraEssential thrombocythemiaGuideline publicationCelgene CorporationCytoreductive therapyHU useMonthly proportionBoehringer IngelheimLarge population-based cohortAdvisory CommitteeDaiichi SankyoOlder adultsEuropean LeukemiaNet guidelinesEnd Results-MedicareProportion of patientsHealthcare Common Procedure Coding System codesPopulation-based studyPatterns of careTreatment of patientsPart D claimsClinical Effectiveness of Hypomethylating Agents (HMAs) and Lenalidomide (Len) in Older Patients (pts) with Refractory Anemia with Ring Sideroblasts: A Large Population-Based Study in the United States (US)
Wang X, Wang R, Zhang C, Zeidan A, Podoltsev N, Huntington S, Gore S, Davidoff A, Ma X. Clinical Effectiveness of Hypomethylating Agents (HMAs) and Lenalidomide (Len) in Older Patients (pts) with Refractory Anemia with Ring Sideroblasts: A Large Population-Based Study in the United States (US). Blood 2019, 134: 4748. DOI: 10.1182/blood-2019-128821.Peer-Reviewed Original ResearchPopulation-based studyLR-MDSMedian overall survivalOverall survivalClinical effectivenessHypomethylating agentCelgene CorporationMedian durationRed blood cellsMedian timeRing sideroblastsBoehringer IngelheimAdvisory CommitteeLarge population-based studyDaiichi SankyoOlder adultsAbnormal erythroid precursorsTransfusion independence rateEnd Results-MedicareHigh-risk MDSErythropoiesis-stimulating agentsKaplan-Meier statisticsComparative clinical effectivenessEnd of studyPart D coverageIncidence and Risk Factors of Second Malignancies Among Medicare Beneficiaries with Newly-Diagnosed Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms Receiving Cytoreductive Therapy with Hydroxyurea
Wang R, Shallis R, Huntington S, Zeidan A, Gore S, Davidoff A, Ma X, Podoltsev N. Incidence and Risk Factors of Second Malignancies Among Medicare Beneficiaries with Newly-Diagnosed Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms Receiving Cytoreductive Therapy with Hydroxyurea. Blood 2019, 134: 330. DOI: 10.1182/blood-2019-127568.Peer-Reviewed Original ResearchMyeloid hematological malignanciesHU usersPopulation-based studyHematological malignanciesCumulative incidenceCelgene CorporationMPN diagnosisCytoreductive therapySolid malignanciesGray's testPolycythemia veraMPN patientsEssential thrombocythemiaContinuous Part D coverageBoehringer IngelheimAdvisory CommitteeLarge population-based studyDaiichi SankyoImpact of hydroxyureaRetrospective cohort studyElixhauser comorbidity scorePV/ET myelofibrosisRisk regression modelsSAS version 9.4Part D coverage
2018
The impact of phlebotomy and hydroxyurea on survival and risk of thrombosis among older patients with polycythemia vera
Podoltsev NA, Zhu M, Zeidan AM, Wang R, Wang X, Davidoff AJ, Huntington SF, Giri S, Gore SD, Ma X. The impact of phlebotomy and hydroxyurea on survival and risk of thrombosis among older patients with polycythemia vera. Blood Advances 2018, 2: 2681-2690. PMID: 30333100, PMCID: PMC6199652, DOI: 10.1182/bloodadvances.2018021436.Peer-Reviewed Original ResearchConceptsRisk of thrombosisPV patientsOverall survivalThrombotic eventsMultivariable Cox proportional hazards modelsEnd Results-Medicare databaseHigh-risk PV patientsCox proportional hazards modelOlder adultsImpact of phlebotomyRetrospective cohort studyPopulation-based studyProportional hazards modelEffect of phlebotomyOutcomes of interestPolycythemia vera patientsContemporary clinical practiceImproved OSCohort studyCytoreductive therapyOlder patientsTherapeutic phlebotomyTreatment modalitiesCurrent guidelinesLower risk
2017
Risk of myeloid neoplasms after radiotherapy among older women with localized breast cancer: A population-based study
Zeidan AM, Long JB, Wang R, Hu X, Yu JB, Huntington SF, Abel GA, Mougalian SS, Podoltsev NA, Gore SD, Gross CP, Ma X, Davidoff AJ. Risk of myeloid neoplasms after radiotherapy among older women with localized breast cancer: A population-based study. PLOS ONE 2017, 12: e0184747. PMID: 28902882, PMCID: PMC5597231, DOI: 10.1371/journal.pone.0184747.Peer-Reviewed Original ResearchConceptsBreast cancer survivorsMyeloid neoplasmsCancer survivorsBreast cancerOlder womenOlder breast cancer survivorsTherapy-related myeloid neoplasmsCompeting-risks survival analysisAbsolute risk increaseBenefits of radiotherapyPopulation-based studyAbsence of chemotherapyRisk of developmentMultiple sensitivity analysesEligible patientsSubsequent chemotherapyAdjuvant radiotherapyLocalized diseaseCumulative incidenceInitial treatmentSEER registryPoor outcomeTreatment recommendationsMedicare claimsMN diagnosisA call for action: Increasing enrollment of untreated patients with higher‐risk myelodysplastic syndromes in first‐line clinical trials
Zeidan AM, Stahl M, Sekeres MA, Steensma DP, Komrokji RS, Gore SD. A call for action: Increasing enrollment of untreated patients with higher‐risk myelodysplastic syndromes in first‐line clinical trials. Cancer 2017, 123: 3662-3672. PMID: 28759108, DOI: 10.1002/cncr.30903.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsHigh-risk myelodysplastic syndromeAZA-001 trialClinical trialsMinimal survival gainsLarge randomized trialsManagement of patientsPopulation-based studyClinical trial enrollmentQuality of lifeMonotherapy armMedian survivalRandomized trialsSurvival impactTrial enrollmentSurvival gainMyelodysplastic syndromeRegistry analysisAggressive malignancyPatientsNatural historyRoutine useTrialsSurvivalEnrollmentHMAsHypomethylating agent (HMA) therapy use and survival in older patients with higher risk myelodysplastic syndromes (HR-MDS) in the United States (USA): A large population-based study.
Zeidan A, Hu X, Long J, Wang R, Huntington S, Podoltsev N, Giri S, Stahl M, Gore S, Ma X, Davidoff A. Hypomethylating agent (HMA) therapy use and survival in older patients with higher risk myelodysplastic syndromes (HR-MDS) in the United States (USA): A large population-based study. Journal Of Clinical Oncology 2017, 35: 7057-7057. DOI: 10.1200/jco.2017.35.15_suppl.7057.Peer-Reviewed Original ResearchOverall survivalHR-MDSDiagnosis yearUS population-based analysisEnd Results-Medicare dataHigh-risk myelodysplastic syndromeLarge population-based studyConventional care regimensMedian overall survivalRetrospective cohort studyRisk myelodysplastic syndromesPopulation-based studyRecent registry dataPopulation-based analysisUse of decitabineAZA-001Unselected natureCohort studyConventional careExcess blastsOlder patientsTherapy usePatient selectionSurvival prolongationCare regimens
2015
80 SUBSEQUENT MYELODYSPLASTIC SYNDROMES IN PROSTATE CANCER PATIENTS AFTER RADIOTHERAPY, A POPULATION-BASED STUDY
Wane R, Zeidan A, Soulos P, Yu J, Davidoff A, Gore S, Gross C, Ma X. 80 SUBSEQUENT MYELODYSPLASTIC SYNDROMES IN PROSTATE CANCER PATIENTS AFTER RADIOTHERAPY, A POPULATION-BASED STUDY. Leukemia Research 2015, 39: s39. DOI: 10.1016/s0145-2126(15)30081-3.Peer-Reviewed Original ResearchVariations in erythropoiesis-stimulating agent administration in transfusion-dependent myelodysplastic syndromes impact response
Duong VH, Baer MR, Hendrick F, Weiss SR, Sato M, Zeidan AM, Gore SD, Davidoff AJ. Variations in erythropoiesis-stimulating agent administration in transfusion-dependent myelodysplastic syndromes impact response. Leukemia Research 2015, 39: 586-591. PMID: 25869077, PMCID: PMC4441842, DOI: 10.1016/j.leukres.2015.03.013.Peer-Reviewed Original ResearchConceptsErythropoiesis-stimulating agentsUse of darbepoetinTransfusion independenceESA initiationTransfusion dependenceMyelodysplastic syndromeESA useTransfusion-dependent MDS patientsRed blood cell transfusionNumber of weeksCox proportional hazards modelErythropoiesis-stimulating agent administrationEnd Results-MedicareWeeks of therapyBlood cell transfusionWeeks of treatmentPopulation-based studyKaplan-Meier statisticsProportional hazards modelAssociation of timingHigh response rateCell transfusionEarly administrationSurveillance EpidemiologyESA administration